OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the…
Myeloma
The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and…
The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone…
MYELOMA
FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat newly diagnosed multiple myeloma patients…
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on venetoclax’s multiple myeloma trials after new safety concerns were raised during…
The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial…
A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health Service (NHS) in England for…
MYELOMA
Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma
Janssen has is seeking approval from the U.S. Food and Drug Administration (FDA) for Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and…
NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation…
A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma,…
Recent Posts
- Early ovarian cancer trial seeking participants to test higher therapy dose
- As a caregiver, I’ve learned to read my mum’s daily forecast
- Short radiation course may ease painful myeloma bone lesions
- Nearly 70% of those given approved myeloma therapy alive 5 years later
- Latest AACR progress report on myeloma is a superpower of good news